Sun Pharma & Moebius Reveal Promising MM-II Osteoarthritis Data
ECONOMY & POLICY

Sun Pharma & Moebius Reveal Promising MM-II Osteoarthritis Data

Sun Pharmaceutical Industries Limited (Sun Pharma) and Israel-based Moebius Medical have jointly announced the publication of two peer-reviewed articles in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI). These publications present key clinical and mechanistic findings on MM-II, an innovative, non-opioid treatment designed to relieve symptoms of knee osteoarthritis (OA).

MM-II is formulated as a proprietary suspension of large, empty, multilamellar liposomes. It aims to reduce joint friction and wear, ultimately alleviating pain and preserving joint health. The two new publications detail the product's significant pain relief results and unique cartilage-protective mechanism.

Key Publication Highlights:

Clinical Efficacy: The first study shares data from a Phase 2b randomised, double-blind, placebo-controlled clinical trial (NCT04506463), involving 397 participants across the US, Europe, and Asia. A single MM-II injection delivered sustained and meaningful pain relief for up to 26 weeks, with a favourable safety and tolerability profile. Read more

Mechanism of Action: The second article, titled “Empty large liposomes reduce cartilage degeneration in osteoarthritic rats by forming a lubricative coating,” reveals MM-II’s action at the cartilage level. It demonstrates that MM-II forms a lubricative layer over cartilage surfaces, reducing mechanical wear and slowing cartilage degeneration—mechanisms that may contribute to its long-term analgesic effects.

Sun Pharmaceutical Industries Limited (Sun Pharma) and Israel-based Moebius Medical have jointly announced the publication of two peer-reviewed articles in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI). These publications present key clinical and mechanistic findings on MM-II, an innovative, non-opioid treatment designed to relieve symptoms of knee osteoarthritis (OA). MM-II is formulated as a proprietary suspension of large, empty, multilamellar liposomes. It aims to reduce joint friction and wear, ultimately alleviating pain and preserving joint health. The two new publications detail the product's significant pain relief results and unique cartilage-protective mechanism. Key Publication Highlights: Clinical Efficacy: The first study shares data from a Phase 2b randomised, double-blind, placebo-controlled clinical trial (NCT04506463), involving 397 participants across the US, Europe, and Asia. A single MM-II injection delivered sustained and meaningful pain relief for up to 26 weeks, with a favourable safety and tolerability profile. Read more Mechanism of Action: The second article, titled “Empty large liposomes reduce cartilage degeneration in osteoarthritic rats by forming a lubricative coating,” reveals MM-II’s action at the cartilage level. It demonstrates that MM-II forms a lubricative layer over cartilage surfaces, reducing mechanical wear and slowing cartilage degeneration—mechanisms that may contribute to its long-term analgesic effects.

Next Story
Equipment

Handling concrete better

Efficiently handling the transportation and placement of concrete is essential to help maintain the quality of construction, meet project timelines by minimising downtimes, and reduce costs – by 5 to 15 per cent, according to Sandeep Jain, Director, Arkade Developers. CW explores what the efficient handling of concrete entails.Select wellFirst, a word on choosing the right equipment, such as a mixer with a capacity aligned to the volume required onsite, from Vaibhav Kulkarni, Concrete Expert. “An overly large mixer will increase the idle time (and cost), while one that ..

Next Story
Real Estate

Elevated floors!

Raised access flooring, also called false flooring, is a less common interiors feature than false ceilings, but it has as many uses – if not more.A raised floor is a modular panel installed above the structural floor. The space beneath the raised flooring is typically used to accommodate utilities such as electrical cables, plumbing and HVAC systems. And so, raised flooring is usually associated with buildings with heavy cabling and precise air distribution needs, such as data centres.That said, CW interacted with designers and architects and discovered that false flooring can come in handy ..

Next Story
Infrastructure Urban

The Variation Challenge

A variation or change in scope clause is defined in construction contracts to take care of situations arising from change in the defined scope of work. Such changes may arise due to factors such as additions or deletions in the scope of work, modifications in the type, grade or specifications of materials, alterations in specifications or drawings, and acts or omissions of other contractors. Further, ineffective planning, inadequate investigations or surveys and requests from the employer or those within the project’s area of influence can contribute to changes in the scope of work. Ext..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?